Mar 04, 2020
Nearly $4 Million In Research Funding For Promising New Treatments In Alzheimer's And Other Dementia
Jan 27, 2020
Applied BioMath, LLC Announces Poster Presentation at the Tau2020 Global Conference
Nov 21, 2019
Initiation of a Phase 2 Multicenter Study of 18F-APN-1607, a Novel Diagnostic PET Imaging Tracer for the Characterization of Tau Burden in Alzheimer's Disease
Nov 20, 2019
New Research Demonstrates Second Direct Link Between Inflammasome Activation and Alzheimer's Disease
May 20, 2019
Asceneuron Appoints Experienced CNS Clinician Dr Eric Yuen to the Board of Directors
Mar 29, 2019
Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
Jan 17, 2019
Asceneuron Appoints Peter Van Vlasselaer as Chairman
Jan 02, 2019
APRINOIA Therapeutics Licenses Tau PET Imaging Tracer APN-1607 to Celgene
Dec 12, 2018
Lilly and AC Immune Announce License and Collaboration Agreement
Dec 06, 2018
Asceneuron Appoints Dr. Thomas C. Wessel as Chief Medical Officer
Nov 20, 2018
Asceneuron Initiates Neuroimaging Trial for Tau Modifier ASN120290
Nov 06, 2018
Rainwater Charitable Foundation Launches World's Largest Prize for Brain Research
Oct 31, 2018
ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias
Jul 18, 2018
Asceneuron's Tau Modifier ASN120290 Receives Orphan Drug Designation for Progressive Supranuclear Palsy From the FDA
Dec 12, 2017
AXON Meets the First Milestone in an nfvPPA Phase 1 Study With AADvac1